Publicaties
Targeted therapy of TERT-rearranged neuroblastoma with BET bromodomain inhibitor and proteasome inhibitor combination therapy Universiteit Gent
Radionuclide imaging and therapy of bone metastases in the era of targeted therapy Universiteit Antwerpen
Drug therapy in children, a special science? : with special emphasis on V2 receptor targeted therapy Universiteit Gent
Biological carrier molecules of radiopharmaceuticals for molecular cancer imaging and targeted cancer therapy Vrije Universiteit Brussel
Nanobody-Based Delivery Systems for Diagnosis and Targeted Tumor Therapy Vrije Universiteit Brussel
The development of innovative targeted therapeutic approaches are expected to surpass the efficacy of current forms of treatments and cause less damage to healthy cells surrounding the tumor site. Since the first development of targeting agents from hybridoma's, monoclonal antibodies (mAbs) have been employed to inhibit tumor growth and proliferation directly or to deliver effector molecules to tumor cells. However, the full potential of such ...
Targeted radionuclide therapy with low and high-dose Lutetium-177 labeled single domain antibodies induces distinct immune signatures in a mouse melanoma model Vrije Universiteit Brussel
Targeted radionuclide therapy (TRT) using probes labeled with Lutetium-177 represents a new and growing type of cancer therapy. We studied immunological changes in response to TRT with Lutetium-177 labeled anti-human CD20 camelid single domain antibodies (sdAbs) in a B16-melanoma model transfected to express human CD20, the target antigen, and ovalbumin, a surrogate tumor antigen. High-dose TRT induced melanoma cell death, calreticulin ...
Evaluation of an Anti-HER2 Nanobody Labeled with 225Ac for Targeted α-Particle Therapy of Cancer Vrije Universiteit Brussel
Human epidermal growth factor receptor type 2 (HER2) is overexpressed in numerous carcinomas. Nanobodies (Nbs) are the smallest antibody-derived fragments with beneficial characteristics for molecular imaging and radionuclide therapy. Therefore, HER2-targeting nanobodies could offer a valuable platform for radioimmunotherapy, especially when labeled with α-particle emitters, which provide highly lethal and localized radiation to targeted ...
Radiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancer Vrije Universiteit Brussel
The integration of diagnostic testing for the presence of a molecular target is of interest to predict successful targeted radionuclide therapy (TRNT). This so-called 'theranostic' approach aims to improve personalized treatment based on the molecular characteristics of cancer cells. Moreover, it offers new insights in predicting adverse effects and provides appropriate tools to monitor therapy responses. Recent findings ...